MSB 3.21% $1.13 mesoblast limited

Over $2buck hit, page-3

  1. 315 Posts.
    lightbulb Created with Sketch. 16
    It appears the FDA aren't convinced it works. The only published RCT says it doesn't. I think I see the problem.
    ' Remestemcel-L did not meet the primary endpoint of greater DCR in the intent-to-treat population (35% versus 30%; P = 0.42).'

    Whats all the whining about?

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.